Syndecan-1 – Page 2 – Communicable Diseases Research

Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19

Research

Published on 2021-08-162022-10-29
Journal: Thrombosis Journal [Category] COVID-19,

[키워드] Admission Analysis analyzed Biomarker Care center city classification Clinical data Coronavirus disease 2019 Course COVID-19 COVID-19 patient Critical critical COVID-19 patient critical COVID-19 patients CRP level ELISA endothelial endothelial injury Factor FIVE glycocalyx high mortality intensive care laboratory data LDH no significant difference pathogenesis of COVID-19 Platelet required Result selected severe COVID-19 severe COVID-19 patient severe respiratory failure severity severity of COVID-19 significant difference significantly significantly higher SOFA score Syndecan-1 Temporal therapeutic target two groups university Yokohama
[DOI] 10.1186/s12959-021-00308-4 PMC 바로가기 [Article Type] Research

A possible pathogenic role of Syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19)

코로나바이러스 질병 2019(COVID-19)의 발병기전에서 신데칸-1의 가능한 병원성 역할

Comparative Study

Published on 2021-08-012022-09-11
Journal: International immunopharmacology [Category] 바이오마커,

[키워드] Admission Analysis change changes in conditions control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients CRP demonstrated diagnosed with COVID-19 Disease activity gradually increased healthy healthy subject ICU ICU patient ICU Patients IL-10 IL-18 IL-6 indicated inflammatory markers investigated Iran marker non-ICU non-ICU patient non-ICU patients Pathogenesis pathogenic respiratory respiratory viral infection ROC Curve SARS-CoV-2 serum significantly higher significantly increased significantly lower Syndecan-1 Tehran the disease two groups Viral viral infection with COVID-19
[DOI] 10.1016/j.intimp.2021.107684 PMC 바로가기 [Article Type] Comparative Study

Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate

Research Article

Published on 2021-06-062022-10-31
Journal: Emerging Microbes & Infections [Category] COVID-19, SARS,

Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury

Case Report

Published on 2021-01-272022-10-29
Journal: Thrombosis Journal [Category] COVID-19,

Vascular Endothelial Glycocalyx Damage in COVID-19

Review

Published on 2020-12-192022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS,

Syndecan-1 Attenuates Lung Injury during Influenza Infection by Potentiating c-Met Signaling to Suppress Epithelial Apoptosis

Article

Published on 2016-08-012023-06-24
Journal: American Journal of Respiratory and Critical Care [Category] 신종인플루엔자,

[키워드] c-Met Influenza Lung injury Proteoglycan Syndecan-1
[DOI] 10.1164/rccm.201509-1878OC PMC 바로가기

Endothelial activation, haemostasis and thrombosis biomarkers in Ugandan children with severe malaria participating in a clinical trial

우간다의 중증 말라리아 아동에서 임상 시험에 참여한 내피세포 활성화, 지혈 및 혈전증 바이오마커

Research

Published on 2016-02-022024-08-13
Journal: Malaria Journal [Category] 말라리아,

[키워드] angiopoietins endothelial activation malaria Syndecan-1 von Willebrand factor
[DOI] 10.1186/s12936-016-1106-z PMC 바로가기 [Article Type] Research